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ETHICAL, LEGAL, AND ECONOMIC
CONSIDERATIONS RELATED TO THE MANDATORY




Human papillomavirus (HPV), the most common sexually
transmitted infection, is a group of more than forty related
viruses.1  HPV is transmitted through genital contact and can
infect cells on the surface of the skin, genitals, anus, mouth, and
throat.2  HPV types sixteen and eighteen cause 70% of cervical
cancer, 30% of vaginal and vulvar cancer, and 80% of anal can-
cer, while HPV types six and eleven cause over 90% of the cases
of anogenital warts in both men and women.3  HPV is most com-
mon among women ages twenty to twenty-four, with a prevalence
rate of 45% in this age group, and remains at a rate of 20% for
women ages fifty to fifty-nine.4  Studies suggest that 80% of sexu-
ally active females will contract the virus before the age of fifty.5
It is estimated that approximately twenty million Americans
are currently infected with HPV and that an additional six mil-
lion people become infected each year.6  Most who become
infected with HPV are unaware because the body is typically able
* J.D. Candidate, Notre Dame Law School, 2013; B.A., University of
Notre Dame, 2010.  I would like to thank the 2012–2013 editorial staff of the
Notre Dame Journal of Law, Ethics & Public Policy for their helpful editing.  I would
also like to thank my parents and brothers for their continued love and
encouragement.
1. Genital HPV Infection—CDC Fact Sheet, CTRS. FOR DISEASE CONTROL &
PREVENTION (Aug. 25, 2011) [hereinafter CDC Fact Sheet], available at http://
www.cdc.gov/std/hpv/HPV-Factsheet-Aug-2012.pdf.
2. Cervical Cancer, AM. CANCER SOC’Y (Jan. 18, 2012), http://www.cancer.
org/Cancer/CervicalCancer/DetailedGuide/index.  HPV can even circumvent
the protection of condoms. Id.
3. Harrell W. Chesson et al., Cost-Effectiveness of Human Papillomavirus Vac-
cination in the United States, 14 EMERGING INFECTIOUS DISEASES 244, 244 (2008).
4. Cervical Cancer, supra note 2.
5. Christina O. Hud, Note, The Virginia Gardasil Law: A Constitutional Anal-
ysis of Mandated Protection for Schoolchildren Against the Human Papillomavirus, 17
WASH. & LEE J. CIVIL RTS. & SOC. JUST. 223, 226–27 (2010).
6. CDC Fact Sheet, supra note 1.
611
\\jciprod01\productn\N\NDE\27-2\NDE210.txt unknown Seq: 2  9-MAY-13 13:34
612 NOTRE DAME JOURNAL OF LAW, ETHICS & PUBLIC POLICY [Vol. 27
to clear the infection on its own.7  However, in those cases caused
by high-risk oncogenic HPV types, the infection can become
chronic and frequently causes cervical cancer.8  Cervical cancer is
one of the most common female malignancies worldwide.9  In
2012, an estimated 12,170 new cases of invasive cervical cancer
will be diagnosed in the United States alone and 4220 women
will die from the disease.10
In June 2006, the Food and Drug Administration (FDA)
approved a new vaccine for women, Gardasil, produced by the
pharmaceutical company Merck, that protects against infection
by certain strains of HPV, including the two strains that cause
most cases of cervical cancer.11  This quadrivalent vaccine is
intended to prevent four strains of HPV associated with cervical
cancer, precancerous genital lesions, and genital warts, and has
been approved by the FDA for use in girls and women ages nine
to twenty-six.  Since the vaccine has the greatest benefit when it is
administered before a person becomes sexually active, the Advi-
sory Committee on Immunization Practices of the Centers for
Disease Control and Prevention recommends that the target pop-
ulation for routine immunization should be adolescents who are
7. Cervical Cancer, supra note 2.  Because most HPV strains do not cause
pain or have easily recognizable symptoms, many people do not know they are
infected or that they are transmitting the virus to a partner.  Additionally, an
individual can develop HPV even after years have passed since the last sexual
contact with an infected person because certain strains linger in the body.  This
lack of recognition or awareness of transmission makes HPV prevention espe-
cially difficult. Id.
8. Id.
9. Pang-Hsiang Liu et al., Cost-Effectiveness of Human Papillomavirus Vacci-
nation for Prevention of Cervical Cancer in Taiwan, 10 BMC HEALTH SERVS. RES. 11,
11 (2010).  Only breast cancer, accounting for twelve percent of all female can-
cers, is ahead of cervical cancer in terms of deadliest female diseases. Id.
10. Cervical Cancer, supra note 2.
11. HPV Vaccine: Implementation and Financing Policy in the U.S., HENRY J.
KAISER FAMILY FOUND., http://www.kff.org/womenshealth/upload/7602_02.
pdf (last visited Apr. 4, 2013) [hereinafter HPV Vaccine].  Controversially, the
FDA also approved Gardasil for men in October of 2009.  Many opponents of
the mandatory vaccine for females have angrily pointed to the Equal Protection
Clause of the Constitution as a defense.  As an example, Dr. Anne Szarewski, a
clinical consultant at Cancer Research UK, has said, “vaccinating only girls is a
shortsighted and potentially damaging strategy . . . [and] reinforces the idea
that sexual health is solely a female concern . . . .”  Rebecca E. Skov, Examining
Mandatory HPV Vaccination for All School-Aged Children, 62 FOOD & DRUG L.J. 805,
817 (2007); see also Lawrence O. Gostin, Mandatory HPV Vaccination and Political
Debate, 306 J. AM. MED. ASS’N 1699, 1700 (2011) (discussing how the “lack of
gender equity remains ethically troubling” and that the HPV vaccine is the first
mandated for only one gender).  Although equal protection issues will not be
addressed in this Note, the continuing controversy over a mandatory HPV vac-
cine for males will be a fascinating debate to watch unfold in the near future.
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approximately twelve years of age, while women ages thirteen to
twenty-six should be given a “catch-up” vaccination.12  Research
suggests “[t]he efficacy of this vaccine is almost 100% if given to
young women before sexual exposure.”13  However, “[w]omen
already infected with HPV [may still] benefit from the vaccine
because it can prevent infection by other HPV strains not yet con-
tracted.”14  In order to be effective, Gardasil must be injected in
three doses over six months.15  Before the development of HPV
vaccines like Gardasil, a widely used screening procedure known
as a Papanicolaou (Pap) test provided the most effective avenue
for preventing cervical cancer.16  The Pap test, which detects
changes in the cervix before cancer develops, remains critical for
early detection even in those who have received the HPV
vaccine.17
Recognizing the significance of the vaccine, legislatures
across the country quickly proposed new laws requiring vaccina-
tion for school-age girls.  The ethical and legal issues surround-
ing mandatory HPV vaccination for school-age girls has
generated significant public debate.  As such, Part II of this Note
will summarize the major arguments that have been presented
on both sides of the debate, discuss state legislative activity con-
cerning the vaccine, and explore the boundaries of vaccination
exemptions.  While the strong push-back from various interest
groups is understandable, this Note will support moving towards
mandatory vaccination while recognizing the necessity for
exemptions, ongoing education, and a sensitivity to opposing
views.  Part III will explore the strengths and weaknesses of an
economic analysis of mandatory HPV vaccination.  This Note will
argue that as societies with finite resources cope with the funda-
mental question of what an extra year of life is worth, sophisti-
cated economic analyses regarding the cost-effectiveness of the
HPV vaccine and other types of medical care will become increas-
ingly influential.
From the outset, it is important to understand that the epi-
demic of cervical cancer and other HPV-related diseases is differ-
ent than epidemics that have led to mandatory vaccination in the
past.  The issues surrounding HPV vaccination are more complex
and controversial.  Unlike the airborne diseases which have war-
ranted mandatory vaccinations, HPV is influenced by personal
12. HPV Vaccine, supra note 11.
13. Chesson et al., supra note 3, at 244.
14. HPV Vaccine, supra note 11.
15. Id.
16. Cervical Cancer, supra note 2.
17. HPV Vaccine, supra note 11.
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risk-taking sexual behavior.  In fact, the HPV vaccine is the first
example where the nature of the activity required to contract the
disease is the primary source of controversy.18  As such, debates
concerning the vaccine are highly personal and highly charged,
with strong moral and religious overtones.
Given that the FDA granted approval of Gardasil in 2006,
the debate about the vaccine has only just begun.  This Note is an
opportunity to explore some of the ethical, legal, economic, and
public policy issues of this debate as medical societies develop
their recommendations, vaccination programs take shape within
states, and legislatures and courts decide the correct balance
between individual rights and the common good.
II. THE DEBATE OVER MANDATING HPV VACCINATION
A. Public Resistance to Compulsory HPV Vaccination
The relatively recent development of the HPV vaccine marks
a major advance in public health.  The vaccine has the potential
to save millions of people from cancer and protect a broad popu-
lation against painful HPV-related infections.  Given these clear
benefits, opposing government-mandated HPV vaccination may
seem inexplicable or even irresponsible.  However, this “miracle
drug” has been resisted on philosophical, political, and ideologi-
cal grounds.19  Arguments against a mandated vaccine illuminate
the unique ethical and legal issues surrounding laws making vac-
cination compulsory.  A brief summary of the major issues raised
is necessary before advocating for a cautious, yet receptive
approach to a mandatory HPV vaccine.
First, opponents argue that mandating the HPV vaccine rep-
resents an encroachment on parental autonomy.  The Supreme
Court has long recognized that parental rights are fundamental
and sanctified in the language of the Due Process Clause of the
Fourteenth Amendment.  The Court acknowledged this right in
Meyer v. Nebraska, holding that parents have the right to “establish
a home and bring up children.”20  As such, requiring school-age
girls to receive the vaccine “takes away the responsibility for par-
18. Felicia B. Eshragh, Note, Same Debate, Different Result: Parental Opt-Outs
of a Mandated HPV Vaccine, 2 ST. LOUIS U. J. HEALTH L. & POL’Y 205, 217 (2008).
19. Hud, supra note 5, at 224.
20. Meyer v. Nebraska, 262 U.S. 390, 399 (1923).  In Prince v. Massachu-
setts, the Supreme Court qualified the holding in Meyer and found that “the
state has a wide range of power for limiting parental freedom and authority in
things affecting the child’s welfare; and that this includes, to some extent, mat-
ters of conscience and religious conviction.”  Prince v. Massachusetts, 321 U.S.
158, 167 (1944).  Basically, children should not be denied protection from HPV
because of their parents’ personal beliefs.  Hud, supra note 5, at 254.
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ents to be the primary decision-makers regarding children’s
health . . . .”21  From this perspective, whether or not to have a
child receive a vaccine that protects against a sexually transmit-
ted virus “should reside strictly within the family,” and
“[l]egislating its use is inappropriately paternalistic.”22  Parents
concerned about the unknown long-term health effects of the
vaccine argue that they should be able to “protect their children
from the potentially ill effects of reckless public policy, and
[that] their inability to do so is an affront to principles of individ-
ual justice.”23
Arguments concerning the scope of parental autonomy are
bolstered by the nature of the disease itself.  HPV is not casually
transmitted.  Unlike diseases such as measles, smallpox, or
chickenpox, HPV is not an airborne, highly infectious disease
that is directly communicable in a school setting.  As such, it is
argued that “the government should not intervene when a virus
can be curbed by changing behavior . . . .”24  Given the marked
differences in communicability when compared to other epi-
demic diseases, there is a “less compelling rationale for requiring
protection against it . . . .”25  Furthermore, some opponents
argue that “[a]lthough it is true that many women suffer from
cervical cancer, it is hardly a public health risk when compared
to the millions affected by epidemics in the last century.”26
Therefore, it is argued, since the disease can be prevented
through a change in behavior and since it does not amount to a
public health emergency, requiring the vaccine represents an
intrusive and unnecessary infringement on parental autonomy.
Additionally, concerns regarding excessive state police
power have also been raised.  Police power refers to the power of
states under the Tenth Amendment to regulate matters affecting
21. Chris Gaetano, Bill Sparks Debate over Health vs. Parents’ Rights, SENTI-
NEL (Feb. 21, 2007), http://em.gmnews.com/news/2007-02-21/Front_page/
014.html (internal quotation marks omitted).
22. T.P. Collins, The HPV Vaccine, CATH. MED. WKLY., Jan. 12, 2007, http:/
/cathmedweek.blogspot.co.uk/2007/01/hpv-vaccine.html.
23. John D. Blum & Norchaya Talib, Balancing Individual Rights Versus Col-
lective Good in Public Health Enforcement, 25 MED. & L. 273, 279 (2006).
24. Katherine S. Homan, Note, Do the Ends Justify the Means? Compelling the
Use of HPV Vaccination on Men, 27 J. CONTEMP. HEALTH L. & POL’Y 183, 212
(2011).
25. James Colgrove, The Ethics and Politics of Compulsory HPV Vaccination,
355 NEW ENG. J. MED. 2389, 2390 (2006).
26. Homan, supra note 24, at 201–02.  The note further argues that there
are already ways for women to protect themselves, including Pap smears and
more cautious sexual behavior. Id. at 202.
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the health, safety, and general welfare of the public.27  State
police powers extend to inspection, quarantine, and health
laws.28  Arguments have been presented that “there is no legal
support for state-mandated HPV vaccination laws because these
mandates extend beyond a state’s power to compel vaccination
as granted by the Supreme Court . . . and are in contravention of
the U.S. Constitution.”29
Next, opponents argue that mandatory vaccination sends a
message to young girls that pre-marital sex with multiple partners
is both acceptable and expected.  For many religious groups, and
Catholics in particular, a mandated vaccine “undermine[s] absti-
nence-based prevention messages,”30 and “sends a message to
both children and society that sexual intercourse is acceptable
behavior for pre-adolescents and adolescents as long as children
are protected from the physical consequences of such con-
duct.”31  As such, vocal Catholics contend that mandatory HPV
vaccination violates the foundational teachings of the Catholic
Church, and “neglects to consider the psychological conse-
quences of adolescent sex.”32  In a strongly-worded response to
proposed legislation mandating the vaccine, an article in Catholic
Medical Weekly concluded that “[r]equiring HPV immunizations
for young girls . . . is . . . no different from requiring that all
school age girls be put on contraception.”33  Similarly, Focus on
27. Carrie A. Roll, Note, The Human Papillomavirus Vaccine: Should It Be
Mandatory or Voluntary?, 10 J. HEALTH CARE L. & POL’Y 421, 428–29 (2007).
28. Gibbons v. Ogden, 22 U.S. 1, 16 (1824).
29. Lindsey Heinz, Note, “Please Don’t Shot My Daughter!” Is There Legal Sup-
port for State-Compelled HPV Vaccination Laws? Why Ethical, Moral, and Religious
Opposition to These Laws May Be Jumping the Gun, 56 U. KAN. L. REV. 913, 914
(2008).
30. Colgrove, supra note 25, at 2389; see also Christy Hoppe, Perry Orders
HPV Vaccine, DALLAS MORNING NEWS, Feb. 3, 2007, http://31.216.132.122/web/
www.data-yard.net/10t2/cancer_vaccine_mandatory.htm (presenting a similar
idea that mandating the vaccine sends a message that the state expects young
girls to have sex). But see God, Sex, Drugs and Politics: A New Vaccine Sparks Contro-
versy, ECONOMIST, Feb. 8, 2007, http://www.economist.com/node/8677214.  In
response to arguments that his controversial executive order mandating the
vaccine for school-age girls in Texas encourages promiscuity, Governor Rick
Perry responded, “‘[i]f the medical community developed a vaccine for lung
cancer . . . would the same critics oppose it, claiming it would encourage smok-
ing?’” Id.
31. Darryn Cathryn Beckstrom, Note, Human Papillomavirus Vaccine Legis-
lation: Are We Oversexualizing Our Youth?, 2 U. ST. THOMAS J. L. & PUB. POL’Y 109,
114 (2008).
32. Id. at 110.
33. Collins, supra note 22.  Although The National Catholic Bioethics
Center authorized a statement that “[t]he NCBC considers HPV vaccine to be a
morally acceptable method of protecting against this disease,” it asked that
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the Family, a Christian group, has warned that “HPV vaccines do
not, in any circumstance, negate or substitute the best health
message of sexual abstinence until marriage and sexual faithful-
ness after marriage.”34  In sum, the possibility of young girls view-
ing a mandated vaccine as an endorsement of promiscuous
behavior has ignited forceful opposition from many religious
groups.
Finally, opponents argue that it is important to remember
Merck (a large pharmaceutical company) stands to make a sub-
stantial profit if mandatory HPV vaccination is enforced.  If the
vaccine is required as a condition for school entry across the
country, Merck will make an enormous profit totaling billions of
dollars.  Not surprisingly, shortly after FDA approved the vaccine,
Merck initiated an aggressive, nationwide lobbying campaign to
convince state lawmakers to pass favorable legislation, and also
attempted to influence professional medical societies to recom-
mend the vaccine.35  Thus, there is concern that Merck’s power-
ful financial incentive for widespread implementation
complicates the development of a vaccination program desig-
nated as promoting the common good.  Ultimately, opponents
argue that Merck lacks transparency when it comes to harmful
drugs, is driven by profit rather than the public good, and is gen-
erally undeserving of national trust and support.
In response, proponents counter that a mandated HPV vac-
cine does not unduly infringe upon parental autonomy and falls
squarely within the state’s police power.36  In Jacobson v. Massa-
chusetts, the Supreme Court first addressed the issue of
“civil authorities leave this decision to parents and not make such immunization
mandatory.” Id.
34. Skov, supra note 11, at 822.
35. Roll, supra note 27, at 439; see also Katherine A. Fortune, Note, Medical
Miracle or Unnecessary Exercise? The Legal Implications of Mandatory Childhood Vacci-
nation for HPV, 85 U. DET. MERCY L. REV. 203, 214 (2008) (discussing how
Merck is credited with “bankrolling efforts to pass state legislation across the
country to vaccinate girls with Gardasil”).  As an example of excessive lobbying,
“Merck contributed close to $40,000 to political campaigns in Virginia in 2005
and 2006.”  Roll, supra note 27, at 439; see also Gostin, supra note 11, at 1700
(discussing how Merck “donated $28,500 to [Rick Perry’s] gubernatorial cam-
paign and an additional $377,500 to the Republican Governors Association, for
which Perry served as chairman”).
36. Indeed, the majority of courts support substantial deference to states’
police power to require vaccinations.  Thus, “[c]ompulsory vaccination laws . . .
enjoy broad judicial and constitutional support, but have also become the sub-
ject of growing resistance.”  Steve P. Calandrillo, Vanishing Vaccinations: Why Are
So Many Americans Opting Out of Vaccinating Their Children?, 37 U. MICH. J.L.
REFORM 353, 388 (2004).  It is interesting to note that the vaccine’s most promi-
nent supporters are public health organizations including the Centers for Dis-
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mandatory vaccinations, the scope of state police power, and the
parameters of an individual’s right to privacy.37  Jacobson, a Mas-
sachusetts citizen, opposed the smallpox vaccine for philosophi-
cal reasons because he did not believe it was effective.  After
evaluating the Cambridge Board of Health’s order to all city
residents to receive the smallpox vaccine due to a smallpox out-
break in the city, the Court held that protection of the whole
community trumps individual rights in such situations.38  The
Court determined that “the liberty secured by the Constitution of
the United States . . . does not import an absolute right in each
person to be, at all times and in all circumstances, wholly freed
from restraint.”39  In fact, “[u]pon the principle of self-defense,
of paramount necessity, a community has the right to protect
itself against an epidemic of disease which threatens the safety of
its members.”40 The Court thus firmly established the state’s gen-
eral authority to require immunization in the interest of public
safety.  In a subsequent case, Zucht v. King, the Supreme Court
expanded the police power to encompass requiring mandatory
vaccination as a condition of school attendance.41  Applying
Jacobson, the Court reasoned that “a state may, consistently with
the federal Constitution, delegate to a municipality authority to
determine under what conditions health regulations shall
become operative.”42
Proponents of the vaccine therefore argue that, in certain
circumstances, a parent’s right to raise his or her child undis-
turbed is not absolute.  They argue that “[m]inors have a right to
be protected against vaccine-preventable illness, and society has
an interest in safeguarding the welfare of children who may be
harmed by the choices of their parents or guardians.”43  Addi-
tionally, HPV, the most common sexually transmitted infection,
certainly qualifies as a public health threat.  HPV is potentially
deadly and has the ability to spread through society at a high
ease Control and Prevention, the American Academy of Pediatrics, and the
American Academy of Family Physicians.  Gostin, supra note 11, at 1699.
37. 197 U.S. 11 (1905).
38. Id. at 27 (stating that the “community has the right to protect itself
against an epidemic of disease which threatens the safety of its members”).  As
discussed, whether or not HPV is a true threat to the general welfare remains
unsettled.
39. Id. at 26.
40. Id. at 27.
41. 260 U.S. 174 (1922).
42. Id. at 176.
43. Colgrove, supra note 25, at 2390.
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rate.  Thus, its “prevalence in society underscores a need to
act.”44
Proponents have also countered that arguments regarding
the sexual messages of the vaccine miss the point: “[i]t’s not
about having sex or not having sex.  It prevents cancer.”45  As
Kim Gandy, President of The National Organization for Women,
states: “ ‘[o]pposing an effective vaccine that would save hun-
dreds of thousands of women’s lives with the vacuous assertion
that it would lead to promiscuity is inexcusable.’”46  Moreover,
practicing pre-marital abstinence does not necessarily ensure
that a woman will be protected from HPV.  Women may contract
the virus from their husbands or, unfortunately, fall victim to
date rape or other types of sexual assault.47  Finally, proponents
urge that it is critical to recognize the “high prevalence of sexual
conduct occurring among teens today.”48  According to a
national survey, 40% of females reported engaging in sexual
activity by age sixteen, and 70% reported being sexually active by
age eighteen.49  Thus, a mandatory HPV vaccine would “promote
sexual health and awareness,” and provide girls and women with
the means to effectively prevent the disease.50
Ultimately, the debate over a mandated HPV vaccine has
been focused on balancing the collective good against individual
rights.51  In fact, it has been suggested that “[f]ew areas in recent
American public health regulation represent the clash of individ-
ual liberty and the protection of community health better than
the current controversies over the efficacy and safety [of]
mandatory childhood immunizations.”52  In order to strike the
necessary balance, policymakers must weigh interests on both
sides of the scale: protecting privacy rights while looking out for
the interests of the state.  Protection of society demands that
44. Jonathan T. Scott, Note, The Difficult Road to Compelling Vaccination for
Sexually Transmitted Diseases—How Gardasil and Those to Follow Will Change the Way
That States Require Inoculation, 97 KY. L.J. 697, 719 (2009).
45. Janet Elliott & Todd Ackerman, Perry Vaccine Move Stirs Money, Sexual
Concerns, HOUS. CHRON., Feb. 3, 2007, http://www.chron.com/news/health/
article/Perry-vaccine-move-stirs-money-sexual-concerns-1801490.php.
46. Hud, supra note 5, at 242; see also Gostin, supra note 11, at 1700 (argu-
ing that there is “no evidence that HPV vaccines increase sexual activity among
adolescents”).
47. See Skov, supra note 11, at 822.
48. Hud, supra note 5, at 242.
49. See Eshragh, supra note 18, at 211.
50. Fortune, supra note 35, at 216.
51. See Homan, supra note 24, at 206 (“The American legal system aims to
balance the rights of its citizens against the goals of society without upsetting
either.”).
52. Blum & Talib, supra note 23, at 277.
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“[w]here the threats to a population are most serious, individual
rights must be subordinate to the common good.”53
Although strong arguments exist on both sides of the
mandatory vaccination issue, concerns for the common good
seem to outweigh protection of individual rights in this particular
circumstance.  As a New Jersey politician caught in the heat of
the debate offered, “ ‘[t]here are few times where the Legislature
can act to directly save lives.  This is one of those times.  We have
the power to bring an end to a type of cancer . . . . Lives are at
stake, and we can save them.’”54  Research has proven that
“school-based laws are an effective and efficient way of boosting
vaccine-coverage rates.”55  As previously discussed, the “vaccine
has the potential to prevent many cases of cervical cancer and
also reduce the cost and emotional burden for the millions of
women who receive abnormal Pap test results attributable to
HPV infection.”56  The means to prevent a terrible disease have
become available and administering the vaccine to the broadest
population of people should be of paramount concern.  While
educational programs and other methods of persuasion may be
marginally effective, requiring HPV vaccination by law will almost
certainly achieve more widespread protection against the disease
than will policies that rely exclusively on persuasion and
education.
That being said, mandating the HPV vaccine as a condition
for school entry at this time appears premature.  As will be dis-
cussed in Part III, infra, too many unanswered questions remain
about the vaccine, particularly with regards to long-term safety
and efficacy.  The recent hesitation of many states, explored in
Part II.B, infra, suggests that although mandating the vaccine
falls within the state’s police power and is the most effective
means of promoting the public good, legislatures should hold off
until more is known about the drug.  As the debate evolves in the
public arena and in the legislatures, it will be important to
encourage continued research and analysis regarding the vac-
cine, strategies for its implementation, and the public health
consequences, both expected and unexpected, of this new
intervention.
53. Id. at 274.
54. Gaetano, supra note 21.
55. Colgrove, supra note 25, at 2390–91; see also HPV Vaccine, supra note 11
(“Mandatory requirements associated with school entrance have been among
the most effective methods for assuring that vaccines reach the largest share of
the population.”).
56. HPV Vaccine, supra note 11.
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Although HPV is markedly different from other diseases that
have warranted compulsory vaccination in the past, it is neverthe-
less a major public health issue deserving of similar treatment.
However, a more cautious approach is necessary at this point.
This will allow time for more information to be gathered about
the medical and public health aspects of HPV vaccination.  Of
equal importance, this will also permit a continued and vigorous
discussion about the moral and religious issues involved so that
deeply held convictions on all sides can be given the careful con-
sideration they deserve.  Given the unique moral and religious
issues that are so entangled in this debate, a future mandatory
HPV vaccination program must be sure to include well-deline-
ated exemptions allowing people to opt-out for agreed-upon
medical, religious, and philosophical reasons.  Exemptions, espe-
cially on religious grounds, should be strongly supported.
As more states begin to implement HPV vaccination pro-
grams, economic analyses, discussed in Part III, infra, should play
an increasingly influential role in guiding the implementation of
mandatory vaccination programs, so that they not only promote
the common good, but do so in the most sensible and cost-effi-
cient manner.
B. State Legislative Response to the HPV Vaccine
Vaccination requirements for school admission are a matter
of state law.57  “The modern era of compulsory vaccination began
in the 1970s to control indigenous measles, a communicable dis-
ease.”58  The HPV vaccine has sparked a mixed response in legis-
latures across the country.
Since 2006, forty-one states and the District of Columbia
have introduced legislation to educate the public about the HPV
vaccine, and at least twenty-one states have enacted such legisla-
tion.59  Some states, such as New Hampshire and South Dakota,
provide the vaccine at no cost to girls between the ages of eleven
and eighteen.  Legislative action at the state level continues.  As
of March 2013, eight states had proposed HPV-related legislation
for the 2013–2014 sessions.60  Mandating the vaccine, however,
remains controversial.  While a few states have aggressively sup-
ported mandating the vaccine, “the morality question has super-
57. See Eshragh, supra note 18, at 210 (“There are no vaccines mandated
on the Federal level, only through state health departments.”).
58. Homan, supra note 24, at 188.
59. See id. at 211.
60. See HPV Vaccine, NAT’L CONFERENCE OF STATE LEGISLATURES, http://
www.ncsl.org/issues-research/health/hpv-vaccine-state-legislation-and-statutes.
aspx (last updated Apr. 2013).
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seded the public health goals in most state legislatures.”61
Shortly after the Centers for Disease Control and Prevention
approved the HPV vaccine for women, Rick Perry, the Governor
of Texas, passed an executive order mandating the vaccine for all
sixth-grade girls.62  In defending the order, Perry stated that
“‘[r]equiring young girls to get vaccinated before they come into
contact with HPV is responsible health and fiscal policy that has
the potential to significantly reduce cases of cervical cancer and
mitigate future medical costs.’”63  Perry’s executive order, how-
ever, was “angrily overturned by the Texas legislature” just a few
months later.64  Similarly, the Michigan Senate introduced legis-
lation requiring the vaccine for sixth-grade girls, but the bill was
never enacted.  Today, only Virginia and the District of Columbia
have approved school attendance mandates for sixth-grade
girls.65  In Virginia, the possible exemptions for the vaccine are
broad, and parents may easily “opt-out” of the vaccine for their
own personal reasons.66
C. The Boundaries of Vaccination Exemptions
“All states recognize some form of exemption from
mandatory vaccinations.”67  Exemptions may be based on medi-
cal, religious, or philosophical grounds.  For medical exemp-
tions, a doctor must sign a statement declaring that a particular
vaccine would be harmful to the health of the patient.68 A relig-
ious exemption is available for those who believe that administra-
tion of vaccines is contrary to their religious beliefs.69 In general,
courts construe religious exemptions strictly, and insist that
opposition to compulsory vaccination be “genuine, sincere, and
an integral part of the religious doctrine.”70  The least common
type is the philosophical exemption, which allows parents and
children an exception for a philosophical objection to vaccines
that is not based on spiritual or religious grounds.71  For philo-
61. Eshragh, supra note 18, at 210.
62. Tex. Exec. Order No. RP65 (Feb. 2, 2007).
63. Elliott & Ackerman, supra note 45.
64. E.G., The HPV Vaccine: Jabs All Around, ECONOMIST, Sept. 13, 2011,
http://www.economist.com/blogs/democracyinamerica/2011/09/hpv-
vaccine.
65. HPV Vaccine, supra note 60, at 212.
66. Eshragh, supra note 18, at 212–13.
67. Id. at 216.
68. Id.
69. Id.
70. Roll, supra note 27, at 431.
71. Eshragh, supra note 18, at 216.
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sophical exemption, many states require that individuals object
to all vaccines, not just a particular vaccine.72
Exemptions for mandatory immunizations conflict with the
public health concept of “herd immunity.”73  Herd immunity is
“achieved when an ‘entire community is protected against a con-
tagion because a sufficiently large percentage of the group is
immune.’”74  As vaccination levels increase, the entire popula-
tion gains resistance to the disease.
Although the benefits of herd immunity are significant and
the reasoning behind the concept is persuasive, future state legis-
lation concerning mandatory HPV vaccination should include
well-delineated religious exemptions.  No other mandatory vacci-
nation program has been so closely linked with individual moral
and religious beliefs.  An appreciation of this delicate interplay is
necessary for a fair administration of the vaccine.  While the ben-
efits of herd immunity may be compromised by ensuring the
availability of exemptions, those parents who, in good faith,
believe that the vaccine violates fundamental religious teachings
should not be forced to comply with the requirement.  Religious
exemptions for a mandated HPV vaccine, therefore, are both
necessary and just.
III. AN ECONOMIC ANALYSIS OF THE HPV VACCINE
A. Evaluating the Efficacy of HPV Vaccination
Spearheaded by Judge Richard Posner,75 a Law and Eco-
nomics approach to public policy and legal decisions encourages
judges to “engage in cost-benefit, economic analysis of law on the
ground that wealth-maximization [is] a kind of preeminent, legit-
imizing principle of political and legal authority.”76  Encom-
passed within the Law and Economics discipline is the belief that
individuals, societies, and legal systems should pursue effi-
72. Id.
73. For a strong argument against liberal exemptions, see Skov, supra
note 11, at 818.  Skov argues that “ ‘[h]erd immunity is threatened as more and
more parents free ride off the community’s dwindling immunity . . . .’” (quot-
ing Steve P. Calandrillo, supra note 36, at 353).
74. Homan, supra note 24, at 191.
75. It is widely accepted that Richard Posner has played the most critical
role in broadening the scope of Law and Economics throughout the academic
community.  His work, The Economic Analysis of Law, provided “the single most
forceful impetus to the onslaught of economics into law schools.”  John J. Don-
ohue III, Law and Economics: The Road Not Taken, 22 LAW & SOC’Y REV. 903, 911
(1988).  The influence of the movement “has been in no small part due to the
clarity and accessibility of all of Posner’s work.” Id. at 912.
76. Jed Rubenfeld, A Reply to Posner, 54 STAN. L. REV. 753, 766 (2002).
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ciency—“getting the most desirable results from the least
resources.”77  From an economics perspective, greater efficiency
is always a top priority.  Economic analyses of healthcare initia-
tives have become increasingly visible in the public policy and
public health arenas, and have also been the subject of contro-
versy.  Debates concerning how to use a finite amount of money
in a healthcare system which has a seemingly infinite number of
demands have raised uncomfortable issues, including how to pri-
oritize available resources.78  Although far from perfect, mathe-
matical models that attempt to determine the economic impact
of various healthcare programs can be informative and contrib-
ute to policy discussions in a substantive way.  The HPV vaccine
provides an especially rich opportunity for economic analysis,
given the availability of fairly well-developed mathematical mod-
els concerning the disease and the many public health profes-
sionals involved in this area.
A useful economic model of HPV vaccination must account
for the many variables involved and set clear, easily definable out-
comes.  However, given the complexity of the disease and the rel-
atively recent introduction of the vaccine into the marketplace,
this remains a daunting task demanding a combination of sophis-
ticated methodology and reliance upon unsupported assump-
tions.  By taking a brief look at the many uncertainties that
currently affect the validity of cost-effectiveness analyses regard-
ing HPV vaccination, an appreciation of the difficulties inherent
in this approach will be clear.
First, the HPV vaccine, although powerful, is no panacea; in
fact, it could end up being associated with significant untoward
consequences.  According to the Centers for Disease Control and
Prevention, the HPV vaccine is an important layer of protection,
but it is “not a shortcut to prevention.”79  As such, regular Pap
tests retain a critical role in the primary prevention of cervical
cancer.  However, after receiving the vaccine, many women may
no longer feel the need to follow a regular screening schedule or
may incorrectly understand the vaccine as a shield against all
types of sexually transmitted diseases.  The possibility of this
potentially dangerous sense of invincibility has led to a twin fear
of missed Pap tests and riskier sexual behavior.  As an article in
the New England Journal of Medicine cautions, “vaccination against
77. Frank Ackerman & Lisa Heinzerling, Pricing the Priceless: Cost-Benefit
Analysis of Environmental Protection, 150 U. PA. L. REV. 1553, 1560 (2002).
78. For example, debates rage over how much money should be spent on
the last months of one’s life and whether those without financial resources have
a right to organ transplantation.
79. Homan, supra note 24, at 210.
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HPV may . . . alter sexual behavior in the population or lead to a
misperception that screening is no longer necessary.”80  These
fears resonate with some religious groups.  For example, an arti-
cle published in Catholic Medical Weekly warned that although the
vaccine does not offer complete protection, “it’s easy to imagine
a 12 year old . . . who thinks it does.”81  Thus, economic model-
ing of HPV vaccination must deal with the very real possibility of
women failing to comply with a regular screening schedule or
engaging in more high-risk sexual activity.
If these fears are confirmed and vaccination leads to riskier
behavior and lower compliance with recommended cervical can-
cer screening, women who receive the vaccine may eventually
require more medical care than those who remain unvac-
cinated.82  This paradoxical increase in long-term health care
costs would dramatically alter a cost-effectiveness analysis of
mandatory vaccination.  Therefore, it is essential that any eco-
nomic model address this potentially deleterious effect of vacci-
nation before proclaiming that mandatory vaccination is
economically sound.
Next, the long-term health effects of the HPV vaccine itself
are not yet fully known.  As of June 2012, approximately forty-six
million doses of HPV vaccine were distributed in the United
States, and the Vaccine Adverse Event Reporting System
(VAERS) received a total of 20,096 reports of adverse events fol-
lowing vaccination.83  Of the total number of VAERS reports
regarding Gardasil, 8% were considered serious, which is defined
as “an event resulting in [d]eath, [l]ife-threatening illness,
[h]ospitalization, [p]rolongation of existing hospitalization [or
80. Jane J. Kim & Sue J. Goldie, Health and Economic Implications of HPV
Vaccination in the United States, 359 NEW ENG. J. MED. 821, 829 (2008); see also
Gail Javitt et al., Assessing Mandatory HPV Vaccination: Who Should Call the Shots?,
36 J.L. MED. & ETHICS 384, 388 (2008) (raising concerns about “a negative
impact of vaccination on cervical cancer screening programs, which are highly
effective at reducing cervical cancer mortality”); Shalini L. Kulasingam & Evan
R. Myers, Potential Health and Economic Impact of Adding a Human Papillomavirus
Vaccine to Screening Programs, 290 J. AM. MED. ASS’N 781, 788 (2003) (voicing
concerns even before the FDA approved the vaccine that women who are vacci-
nated may feel protected and not participate in screening programs).
81. Collins, supra note 22.
82. Evan Myers et al., The Current and Future Role of Screening in the Era of
HPV Vaccination, 109 GYNECOL. ONCOLOGY S31, S35 (2008) (suggesting that “if
vaccinated women are less likely to adhere to screening recommendations
because of a belief of complete cervical cancer protection, outcomes could
actually worsen”).
83. HPV Vaccine Information for Clinicians—Fact Sheet, CTRS. FOR DISEASE
CONTROL & PREVENTION, http://www.cdc.gov/std/hpv/stdfact-hpv-vaccine-hcp.
htm (last updated July 12, 2012).
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p]ersistent or significant disability.”84  How strongly linked vacci-
nation administration was to these serious events remains
unknown.  What is known is that the vaccine has been on the
market for less than a decade, and the first generation of
targeted eleven- and twelve-year-old girls who received the vac-
cine have not yet reached their reproductive peak.  As such, the
full impact of the HPV vaccine will not be observable for many
years and, therefore, “decisions regarding a vaccination policy
will inevitably [need to] rely on studies reporting intermediate
outcomes.”85  Unfortunately, the current reality is that we do not
know the extent or magnitude of the negative effects associated
with the vaccine.86  Whether the vaccine will lead to more serious
and unpredicted adverse events in the future is an unanswered
question.  Thus, an economic model regarding HPV vaccination
must attempt to address the many lingering questions regarding
the safety of the vaccine, and adequately account for short- and
long-term health effects.
Similarly, the duration of action of the HPV vaccine, desig-
nated as one of “the most important variable[s]” in determining
the vaccine’s impact, also remains an unanswered question.87  If
the vaccine’s protection fades away after several years and addi-
tional shots are necessary, the total cost of administering the vac-
cine increases without a proportional decrease in the cost of
treating cervical cancer and other HPV-related complications in
the future.  As such, economic modeling of HPV vaccination
must deal with the current uncertainty regarding duration of
action.  To date, some mathematical models assume vaccine effi-
cacy lasting ten years then declining to zero without booster
84. Id. Gardasil has also been loosely linked to fifty-three deaths world-
wide. See Hud, supra note 5, at 230.
85. Kim & Goldie, supra note 80, at 822.
86. Javitt et al., supra note 80, at 387–88.  Given the uncertainty about
adverse effects and long-term efficacy, doubts have been raised about compet-
ing agendas (e.g. profit motive for the pharmaceutical companies involved).
One author gave voice to these concerns:
When weighing evidence about risks and benefits, it is also appropri-
ate to ask who takes the risk, and who gets the benefit.  Patients and
the public logically expect that only medical and scientific evidence is
put on the balance.  If other matters weigh in . . . the balance is easily
skewed.
Charlotte Haug, The Risks and Benefits of HPV Vaccination, 302 J. AM. MED. ASS’N
795, 796 (2009).
87. Sarah Jeurissen & Amin Makar, Epidemiological and Economic Impact of
Human Papillomavirus Vaccines, 19 INT’L J. GYNECOL. CANCER 761, 764 (2009).
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shots,88 while others assume lifelong efficacy—assumptions
which dramatically affect the predicted cost-benefit ratios.89
Economic models must also draw a distinction between cost-
effectiveness and affordability.  Medical interventions with high
value are often times not affordable for a significant popula-
tion.90  Gardasil is one of the most expensive vaccines ever devel-
oped.91  Each dose in the three-dose series costs $120, totaling
$360 for the complete vaccine package.  Some private and public
sector payers cover the cost of the vaccine, but “policies vary
regarding the age of the coverage, the reimbursement levels paid
by different payers, and the out-of-pocket costs faced by health
care consumers.”92  This variable insurance coverage coupled
with the vaccine’s cost has the potential to impose significant
financial strain on families.  It is therefore crucial to acknowl-
edge that even if mandatory vaccination is cost-effective on a
national level, it still may be an economic hardship for individu-
als.  Thus, while the vaccine may arguably be cost-effective, it is
certainly not inexpensive and, for this reason, it may not be the
most efficient or attractive health care step for many families to
take.93
The problem of affordability also raises the question of who
should pay for the vaccine.  Should insurance companies be
forced to cover it?  Should low-income families be exempt from
the mandate?  Should the federal government cover the cost?
There is often a tendency to evaluate single diseases or particular
interventions in isolation and fail to understand how they fit into
88. Kulasingam & Myers, supra note 80, at 787.
89. Win Techakehakij & Roger D. Feldman, Cost-Effectiveness of HPV Vacci-
nation Compared with Pap Smear Screening on a National Scale: A Literature Review,
26 VACCINE 6258, 6261 (2008).
90. Jane J. Kim, The Role of Cost-Effectiveness in U.S. Vaccination Policy, 365
NEW ENG. J. MED. 1760, 1760 (2011).
91. Homan, supra note 24, at 196.
92. HPV Vaccine, supra note 11.
93. But see Hud, supra note 5.  Recognizing the financial burden felt by
some families, the federal government provides free vaccination for children up
to age eighteen who are Medicaid eligible and uninsured in its Vaccine for
Children Program.  Additionally, as Dr. Deborah Arrindell, Vice-President of
Health Policy at The American Social Health Organization states, “ ‘[m]iddle
school may be the last public health gate we all walk through together, before
kids begin dropping out of schools or get a crummy job without health insur-
ance, or enter the workforce in general with its fragmented healthcare system.’”
Id. at 246–47 (quoting Karen Houppert, Who’s Afraid of Gardasil?, THE NATION,
Mar. 8, 2007, at 5).  For this reason, the high price tag of the vaccine is arguably
offset.  Interestingly, Merck also created its own program designed to provide
Gardasil to individuals falling below 200 percent of the national poverty line.
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a broader picture.94  Thus, while individual vaccines may appear
cost-effective, the “overall U.S. vaccination program may be unaf-
fordable or provide less value than other bundled preventive
health services targeting the same age group.”95  The issue of
affordability also highlights that cost-effectiveness models need
to consider the role that healthcare access and health disparities
will play.  How will vaccination and screening vary for different
populations and different communities?  Bridging the gap
between cost-effectiveness and affordability is another challeng-
ing task an economic approach must address.
Finally, a multitude of other variables must be dealt with,
including: the possibility of cross-protection against other types
of HPV;96 the phenomenon of “herd immunity”;97 vaccine effi-
cacy;98 the percentage of girls and women predicted to be vacci-
nated;99 the age of onset and frequency of Pap smear screening
recommended;100 predicted compliance with screening, follow-
up, and treatment;101 how costs are calculated (e.g. whether or
not to include indirect expenses);102 outcome parameters (e.g.
whether or not to include the benefits of preventing HPV-related
non-cervical cancers or genital warts);103 and whether a discount
rate is included in the analysis (a discount rate adjusts for the fact
that individuals prefer to receive benefits sooner rather than
94. See, e.g., Javitt et al., supra note 80, at 392.  The potential conse-
quences of a mandated vaccine are varied.  For example, these authors suggest
“[a]dding HPV could drive more states to abandon funding for other vaccina-
tions and could divert funding from other important public health measures.”
Id.  They note that even physicians have argued that “the rising costs of vaccines
and the rising number of new mandatory vaccines make it increasingly difficult
for them to purchase vaccinations initially and that they net a loss due to insuffi-
cient reimbursement from insurers.” Id. at 392–93.
95. Kim, supra note 90, at 1761.
96. See Kim & Goldie, supra note 80, at 826.
97. See Chesson et al., supra note 3, at 246.
98. See Tjalke A. Westra et al., Until Which Age Should Women Be Vaccinated
Against HPV Infection? Recommendation Based on Cost-Effectiveness Analyses, 204 J.
INFECTIOUS DISEASES 377, 379 (2011).
99. See Kulasingam & Myers, supra note 80, at 782.  Some studies assume
100% coverage, while others assume increasing rates, then stabilizing at 70%.
See Techakehakij & Feldman, supra note 89, at 6260.
100. See id.
101. Jaume Puig-Junoy & Beatriz G. Lopez-Valcarcel, Economic Evaluations
of Massive HPV Vaccination: Within-Study and Between Study Variations in Incremen-
tal Cost Per QALY Gained, 48 PREVENTIVE MED. 444, 445 (2009).
102. See Westra et al., supra note 98, at 379.
103. See Fawziah Marra et al., Effectiveness and Cost Effectiveness of Human
Papillomavirus Vaccine: A Systematic Review, 27 PHARMACOECONOMICS 127, 144
(2009).
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later and incur costs later rather than sooner).104  Modeling
needs to consider these and other variables, decide whether or
not they should be included in the analysis, and make assump-
tions regarding those variables included, with little definitive
data backing up the assumptions made.
In short, the HPV vaccine is just too new to fully understand
all of its ramifications, both positive and negative.  As discussed,
many questions remain including the effects of HPV vaccination
on regular screening, unforeseen health consequences that may
arise over time, duration of protection, vaccine affordability,
achievable coverage rates, and the equitability of coverage.105
Given the impressive number of variables and the current uncer-
tainties about which values to assign for each, the assumptions
underlying each of the many existing mathematical models have
a profound influence on their conclusions.106  However, in spite
of all of the unknowns that seriously compromise the accuracy
and usefulness of these predictions, these formal approaches to
analyzing cost-effectiveness have an important role to play in
shaping public policy and legal discussions.107  Rigorous work has
already been devoted to determining the economic impact of dif-
ferent strategies related to the prevention of HPV-related dis-
ease.108  As the HPV vaccine continues to reach a larger
population and as these analyses become increasingly sophisti-
cated and accurate, courts and legislatures will need to remain
aware of the information and insights these models provide.
B. Exploring the Cost-Effectiveness of HPV Vaccination
Legislation mandating certain vaccinations is driven by myr-
iad factors, including “vaccine safety and efficacy, avertable dis-
104. Puig-Junoy & Lopez-Valcarcel, supra note 101, at 445.
105. For a sophisticated analysis of these “parameter uncertainties” that
may cause variations in cost per QALY gained, see Puig-Junoy & Lopez-Val-
carcel, supra note 101.
106. See Jeurissen & Makar, supra note 87, at 761 (stating that cost-effec-
tiveness ratios are extremely varied and highly dependent on assumptions
made).
107. See Marra et al., supra note 103, at 143 (suggesting that mathematical
modeling and economic analyses provide important data for policy decisions).
108. See, e.g., Marc Brisson et al., Economic Evaluation of Human Papil-
lomavirus Vaccination in Developed Countries, 12 PUB. HEALTH GENOMICS 343
(2009).  Although many economic studies are producing consistent conclusions
that vaccinating young girls against HPV is likely to be cost-effective, myriad
challenges remain to be addressed, including the difficulty of measuring simul-
taneously the impact of different prevention strategies such as conventional
screening and vaccination. Id. at 345.
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ease burden, acceptability, and societal value.”109  The cost-
effectiveness of a particular vaccination program is an additional
factor, and one with perhaps the greatest potential to shape
future healthcare policy.  A cost-effectiveness analysis “provides
information on whether the health gain associated with each new
vaccine is worth the cost, as compared with other options for
health spending.”110  In general, a cost-effective vaccine has low
cost, high efficacy, and results in a situation in which “the up-
front expenditure for vaccination is entirely offset by costs
averted through disease prevention.”111  According to this view,
to be considered cost-effective, the expected cost of administer-
ing the HPV vaccine nationwide to school-age girls must be less
than the cost of treating cervical cancer and other HPV-related
diseases.112  Fortunately, as discussed below, this is not the pre-
vailing view, which instead factors the health benefits of a partic-
ular intervention into the equation.  The prevailing view is that
some achievable health benefits—for example, improved quality
of life and/or longer life expectancy—are worth paying for as
long as the incremental cost is below an agreed-upon threshold.
Many recent studies argue that widespread administration of
the HPV vaccine is a cost-effective strategy.  According to
research presented in the New England Journal of Medicine, the
HPV vaccination is expected to be “economically attractive . . . if
high coverage can be achieved in the primary target group of 12-
year-old girls . . . .”113  Similarly, a study presented in the Interna-
tional Journal of Gynecological Cancer suggests that the HPV vaccine
can be cost-effective so long as the duration of vaccine-related
immunity is high, efficacy is high, price is low, and the vaccine is
administered before the onset of sexual activity.114  Regarding
109. Kim, supra note 90, at 1760.
110. Id. at 1761.
111. Id. at 1760.
112. In other words, in order for something to be cost-effective, it must
be efficacious and come at a reasonable price.  What constitutes a reasonable
price will be decided by what society determines is reasonable.  For example, a
$50,000 lifetime incremental expense for each quality-adjusted year of life
gained by vaccinated women may be considered cost-effective.
113. Kim & Goldie, supra note 80, at 827.  Although mandatory vaccina-
tion of school-age boys is beyond the scope of this Note, it is worth mentioning
that the results of at least one study found that “vaccinating boys will most likely
not be cost-effective in countries that can reach high coverage rates in girls.”
See Brisson et al., supra note 108, at 350.
114. Jeurissen & Makar, supra note 87, at 761; see also Marra et al., supra
note 103, at 144–45 (showing that systematic review of the literature has
revealed that a female-only vaccination program added to regular screening is
cost-effective compared with the cytology-based Pap smear screening alone.  All
models showed that the HPV vaccine in females may be considered cost-effec-
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the cost of administering the vaccine, the three-dose series costs a
total of $360, plus the cost of wastage and supplies.  Included
within the vaccine administration cost is the vaccine price and
delivery program costs.  The cost of treating cervical cancer
nationwide, on the other hand, ranges from $300 to $400 million
annually, which includes “direct medical costs associated with
screening, diagnosis, and treatment (such as tests, procedures,
and hospitalizations) . . . .”115
An acceptable method of evaluating the potential cost-effec-
tiveness of a particular strategy like HPV vaccination relies on
what is known as a “QALY” measurement, the incremental cost
per quality-adjusted life year gained.116  QALY is a “metric for
health and longevity that is now widely used by health econo-
mists, public health scholars, and others researching the eco-
nomics of health care,”117 and takes into account measures of
disease burden on the “quality and quantity of life lived.”118
Some have suggested that a strategy may be considered cost-
effective in the United States if the incremental cost-effectiveness
ratio is in the range of $50,000–80,000 per QALY saved.119  In
tive because it produces a cost per QALY ratio below a traditionally used cut-off
of $50,000 per QALY.); Kulasingam & Myers, supra note 80, at 781 (“Vaccina-
tion plus biennial screening delayed until age 24 had the most attractive cost-
effectiveness ratio ($44,889) compared with screening only beginning at 18
years and conducted every three years.  However, the strategy of vaccination
with annual screening beginning at age 18 had the largest overall reduction in
cancer incidence and mortality at a cost of $236,250 per life-year gained com-
pared with vaccination and annual screening beginning at age 22 years.”).
115. Jane J. Kim et al., Cost-Effectiveness of Human Papillomavirus Vaccination
and Cervical Cancer Screening in Women Older Than 30 Years in the United States, 151
ANNALS INTERNAL MED. 538, 540–41 (2009).
116. One such study developed a model to estimate the cost-effectiveness
(cost per QALY) of adding HPV vaccination of twelve-year-old girls to existing
cervical cancer screening practices.  The study included all direct medical costs
and benefits regardless of who incurred the costs or received the benefits.
Results indicated an estimated cost per QALY gained of $3906–$14,723 depend-
ing on a variety of factors.  However, the analysis did not address all of the
potential costs and benefits, including cross-protection against high-risk types of
HPV other than sixteen and eighteen and prevention of other cancers. See
Chesson et al., supra note 3, at 249.
117. Matthew D. Adler, QALYs and Policy Evaluation: A New Perspective, 6
YALE J. HEALTH POL’Y L. & ETHICS 1, 1 (2006).
118. Homan, supra note 24, at 197.
119. Myers et al., supra note 82, at S33.  The oft-quoted acceptable range
of $50,000–$80,000 per QALY is decades old, not evidence-based, and it is
unclear what this value range is today (higher and lower ranges have been sug-
gested).  A recent study, however, confirms that the range quoted above
remains reasonable in today’s market and further notes: “Making decisions that
consider cost effectiveness . . . of healthcare interventions has become increas-
ingly important.”  Takeru Shiroiwa et al., International Survey on Willingness-to-Pay
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studies comparing the cost-effectiveness of an HPV vaccination
program plus regular Pap screening with Pap screening alone,
the range of cost-effectiveness ratios turned out to be between
$16,600 and $27,231 per QALY gained.120  As women age, how-
ever, the cost-effectiveness of the vaccine diminishes.  One study
found that “as the age at vaccination increased so did the cost
per QALY gained.”121  For example, while the cost-effectiveness
ratio for twelve-year-old girls was $43,600 per QALY, the ratio was
$120,400 per QALY for twenty-one-year-old girls, and $152,700
for twenty-six-year-old women.122  This type of analysis, of course,
raises an important and difficult ethical issue: the incidence of
cervical cancer, and its effect on quality of life and life expec-
tancy, can be lessened by initiating Pap screening earlier and
more frequently than currently recommended and by offering
“catch-up” vaccination to women older than eighteen years old;
however, this comes at substantial cost.  How much is a “quality-
adjusted life year” actually worth to United States citizens?  Thus
far, a cost-effectiveness analysis has been used in the public
health policy arena in the United States on a very limited basis, in
contrast to countries such as Australia, Great Britain, Canada,
and New Zealand, “which now regularly evaluate cost-effective-
ness of pharmaceuticals or health technologies proposed for
public reimbursement.”123  As noted, unlike some other coun-
tries, the United States has not agreed upon a cost-effectiveness
threshold for health-related interventions.124
In sum, a large amount of money, time, and brainpower are
currently being expended on QALY research and that research
promises to play an important role in shaping health policy.
Given the growing financial pressures that many countries face
today and will continue to face in the future, this type of eco-
nomic approach is likely to increasingly influence public policy
and legislation.125  In light of the many variables and uncertain-
(WTP) for One Additional QALY Gained: What Is the Threshold of Cost Effectiveness?,
19 HEALTH ECON. 422, 435 (2010).
120. See Techakehakij & Feldman, supra note 89, at 6260–63.  The studies
assumed that the duration of protection with the vaccine ranged from ten years
to a lifetime. Id. at 6260.
121. T.C. Pomfret et al., Quadrivalent Human Papillomavirus (HPV) Vaccine:
A Review of Safety, Efficacy, and Pharmacoeconomics, 36 J. CLINICAL PHARMACY &
THERAPEUTICS 1, 6 (2011).
122. Id.
123. Adler, supra note 117, at 4.
124. Kim, supra note 115, at 543.
125. Cost-effectiveness analysis is also important for medical societies
responsible for developing guidelines for screening and vaccination, as these
guidelines take cost into account.
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ties involved, the approach does not yet appear ready for imple-
mentation; however, even in its current imprecise form, the
approach is able to provide valuable insights about the relative
cost-benefit ratios of different strategies.  Although in its infancy,
cost-effectiveness modeling in HPV programs and numerous
other healthcare initiatives is something to be aware of.  An eco-
nomic approach will undoubtedly expand in influence in the
years to come and affect laws and policies regarding HPV
vaccination.
Designed to influence social policy, a purely economic
approach is flawed and raises more questions than perhaps it
answers.  As the use of cost-effectiveness analyses increases, it is
imperative that limitations of the approach be acknowledged and
addressed.  An article in Preventive Medicine succinctly described
the benefits and limitations of economic modeling:
Economic evaluation models are increasingly sophisti-
cated.  They fit all relevant epidemiologic and economic
data into a set of up to dozens of thousands of plausible
scenarios.  But omni-comprehension of those alternative
worlds created by the modeler in order to give thorough
scientific treatment to epidemiologic and market uncer-
tainty does not compensate for the lack of basic informa-
tion.  Those models are useful for policy purposes only to
the extent they can reduce uncertainty.126
However, despite its shortcomings, cost-effectiveness model-
ing will become more sophisticated and accurate, and will be
increasingly used by politicians, legislatures, and medical socie-
ties in the future.127  As such, it behooves lawyers to be aware of
this type of analysis—its strengths, flaws, and its probable
expanding role in future laws and decision-making.  As we have
learned from Judge Posner, economic considerations should
become a part of our discussions and planning regarding law,
ethics, and public policy.
IV. CONCLUSION
Transmitted exclusively through sexual activity, HPV is
markedly different from other types of diseases that have led to
mandatory vaccinations in the past.  Given HPV’s prevalence in
126. Puig-Junoy & Lopez-Valcarcel, supra note 101, at 446 (citation
omitted).
127. See, e.g., id. (acknowledging the increasing sophistication of eco-
nomic evaluation models regarding the HPV vaccine, but also recognizing that
there remain significant variations in cost per QALY estimates of vaccination
programs around the world).
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society and potentially fatal consequences, Merck’s development
of the HPV vaccine, Gardasil, was revolutionary.  With the intro-
duction of the vaccine came highly publicized controversy over
its safety and appropriateness.  As states began considering a
mandatory HPV vaccination program for school-age girls, the
debates intensified, and opponents drew arguments from legal,
religious, and philosophical grounds.
Those against a mandatory vaccine argue that requiring
HPV inoculation represents an encroachment on parental auton-
omy as well as an excessive exercise of state police power.  As
HPV-related diseases can be prevented through other, less intru-
sive, means such as Pap tests and modified sexual behavior, man-
dating the vaccine can be seen as an affront to individual liberty.
Also, requiring young girls to receive a vaccine that protects
against a sexually transmitted infection has the same effect, some
argue, as expressly encouraging promiscuity.  Add in the enor-
mous profit Merck, a company criticized for its lack of trans-
parency and excessive lobbying, stands to make from widespread
implementation, and mandatory vaccination can then be viewed
as an unwise strategy.
On the other side, proponents insist that mandatory HPV
vaccination falls squarely within a state’s police power as defined
by Supreme Court precedent.  A parent’s right to privacy is not
absolute, they argue, and in certain serious circumstances con-
cern for the common good trumps individual liberty interests.
Moreover, compulsory HPV vaccination aligns with the current
reality of increased sexual activity among young girls.
Although mandatory HPV vaccination for school-age girls
might be implemented in several states in the near future, the
amount of unanswered questions about the safety and efficacy of
the vaccine demand a more cautious approach.  High quality,
unbiased research needs to be done in order to learn even more
about the vaccine, and as the debates surrounding the vaccine
continue, states will ideally take the lead in treating HPV in the
same way as other communicable diseases have been dealt with
in the past.
Mathematical models that attempt to determine the eco-
nomic impact of certain public health strategies will contribute
to the debate in a substantial way as these models become
increasingly accurate and sophisticated.  These models are cur-
rently imprecise, as they are forced to account for a range of vari-
ables of unknown value, including the duration of protection of
the vaccine, the vaccine’s efficacy, effects of the vaccine on sexual
behavior, unequal coverage of populations at risk, and any long-
term health effects of the vaccine.  Yet, they have the potential to
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significantly influence public policy and legal discourse as the
United States determines how best to use a finite amount of
resources.  Becoming familiar with the insights provided by cost-
effectiveness analyses of HPV vaccination programs will enable
those in the legal, public policy, and political arenas to have a
more thorough understanding of this ongoing debate, which will
continue for many more years.
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